论文部分内容阅读
目的研究卡维地洛治疗慢性心力衰竭的疗效及其安全性。方法选择稳定的慢性心力衰竭患者150例,在标准治疗的基础上加用卡维地洛并逐步上调剂量直至靶剂量(或最大耐受剂量),分组比较患者治疗前及治疗后3个月、6个月的心功能分级(NYHA)和心功能指标变化。结果经过3～6个月的观察和治疗,卡维地洛组临床症状和心功能明显改善,左室射血分数(LVEF)增加,左室收缩末期容积和左室舒张末期容积减小,用药中无特殊不良反应。结论卡维地洛在心力衰竭标准治疗基础上应用可以提高射血分数,减小扩大的心室腔,改善心功能,改善心室重塑,用药安全、有效。
Objective To study the efficacy and safety of carvedilol in the treatment of chronic heart failure. Methods 150 patients with stable chronic heart failure were selected. Carvedilol was added to the standard treatment and the dose was increased up to the target dose (or the maximum tolerated dose). The patients in the group were compared before treatment and 3 months after treatment, Six-month cardiac function classification (NYHA) and cardiac function changes. Results After 3 to 6 months of observation and treatment, the clinical symptoms and cardiac function of carvedilol group were significantly improved, the left ventricular ejection fraction (LVEF) increased, the volume of left ventricular end-systolic volume and left ventricular end-diastolic volume decreased, No special adverse reactions. Conclusion Carvedilol can improve the ejection fraction, reduce the enlarged ventricular cavity, improve cardiac function, improve ventricular remodeling and safe and effective treatment based on the standard treatment of heart failure.